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KEBERKESANAN APLIAS ORAL BERBANDING TEKANAN UDARA 
POSITIF BERTERUSAN DALAM RAWATAN APNEA TIDUR 
OBSTRUCTIF: PENYELIDIKAN KLINIKAL RAWAK 
ABSTRAK 
 
Satu kajian klinikal rawak berbentuk selari telah dijalankan di Institut 
Perubatan & Pergigian Termaju (IPPT) Universiti Sains Malaysia (USM) untuk 
menentukan keberkesanan aplians oral (OA) berbanding dengan tekanan udara 
positif berterusan (CPAP) dalam rawatan apnoea tidur obstruktif. Pesakit yang 
dirujuk dari Klinik Telinga, Hidung & Tekak telah disaring untuk kelayakan 
menyertai kajian. Selepas mengambilkira semua kriteria kemasukan dan 
pengecualian, seramai 40 orang pesakit telah diambil dan dibahagikan secara rawak 
kepada dua kumpulan rawatan; 19 orang pesakit dalam kumpulan CPAP dan 21 
pesakit dalam kumpulan OA. Namun, seorang orang pesakit daripada setiap 
kumpulan tidak meneruskan kajian, menjadikan jumlah keseluruhan peserta kajian 
seramai hanya 38 orang, 18 orang pesakit dalam kumpulan CPAP dan 20 pesakit 
dalam kumpulan OA. Ujikaji telah mengambil masa selama sebulan yang mana 
Indeks Apnoea/Hypopnea, ketepuan oksigen nokturnal minima (MinO2) dan 
ketepuan oksigen purata (MeanO2) telah direkodkan sebelum dan selepas rawatan 
bagi kedua-dua kumpulan pesakit dengan menggunakan polisomnografi sepanjang 
malam. Skala Mengantuk Epworth (ESS) dan Indeks Kualiti Kehidupan Apnoea 
Tidur Calgary (SAQLI) versi Bahasa Melayu telah diberikan kepada pesakit sebelum 
dan selepas rawatan, masing-masing untuk menilai perubahan-perubahan dari segi 
xiv 
 
rasa mengantuk pesakit pada siang hari serta kualiti kehidupan yang berhubungkait 
dengan kesihatan. Selepas ujikaji, perubahan signifikan telah dapat dilihat pada skor 
purata ESS (P=0.022), AHI (P˂0.001), MinO2 (P=0.008) dan MeanO2 (P=0.003) 
selesai rawatan menggunakan CPAP tetapi tiada perubahan signifikan didapati pada 
skor SAQLI. Selepas rawatan menggunakan OA, perubahan signifikan pada purata 
skor ESS (P=0.002), AHI (P˂0.001), MinO2 (P=0.019) dan skor SAQLI (P=0.044) 
telah didapati. Bagaimanapun, tiada perbezaan signifikan pada MeanO2. Selepas 
kajian, tiada perbezaan signifikan dilihat pada semua parameter yang dinilai antara 
pesakit dirawat dengan OA dan pesakit dirawat dengan CPAP. Pesakit-pesakit di 
dalam kumpulan OA telah menunjukkan penerimaan dan toleransi yang lebih 
terhadap kesan sampingan yang berkait dengan penggunaan OA sebagai suatu 
kaedah rawatan berbanding dengan pesakit-pesakit di dalam kumpulan CPAP. 
Kesimpulannya, walaupun CPAP kekal sebagai piawaian emas dalam rawatan OSA 
namun OA merupakan satu kaedah rawatan yang berkesan untuk mengurangkan AHI 
dan rasa mengantuk pada siang hari serta menambahbaik MinO2 dan kualiti 
kehidupan yang berkait dengan kesihatan bagi pesakit yang menderita OSA ringan 
sehingga peringkat teruk. Dalam kajian ini, keberkesanan OA didapati setara dengan 
CPAP dalam merawat OSA. 
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THE EFFECTIVENESS OF ORAL APPLIANCE IN COMPARISON 
WITH CONTINUOUS POSITIVE AIRWAY PRESSURE IN THE 
TREATMENT OF OBSTRUCTIVE SLEEP APNOEA: A RANDOMISED 
CLINICAL TRIAL 
ABSTRACT 
 
A parallel design randomised controlled trial was conducted at the Advanced 
Medical and Dental Institute (AMDI) Universiti Sains Malaysia (USM) to determine 
the effectiveness of oral appliances (OA) in comparison to the continuous positive 
airway pressure (CPAP) in the treatment of obstructive sleep apnoea. Patients 
referred from the Ear, Nose and Throat clinic were screened for eligibility to 
participate in the trial. After considering all the inclusion and exclusion criteria, 40 
patients were recruited and were randomised by an online randomization software 
available on (www.randomization.com) which was used to produce a randomization 
plan. This trial was blinded and patients were randomised into two groups by a nurse 
opening a sealed envelope that had been prepared earlier by the researcher which 
contained either the letter A or B. As a result 19 patients in the CPAP group and 21 
patients in the OA group were recruited. However, 1 patient from each group did not 
continue the trial, leaving only 38 study participants in total, 18 patients in the CPAP 
group and 20 patients in the OA group. The trial period was one month. 
Apnoea/Hypopnea index (AHI), minimum nocturnal oxygen saturation (MinO2) and 
mean oxygen saturation (MeanO2) were recorded before and after treatment for 
patients in both groups by overnight polysomnography. Epworth Sleepiness Scale 
xvi 
 
(ESS) and the Malay version of Calgary Sleep Apnoea Quality of Life Index 
(SAQLI) were given to the patients before and after treatment to assess the changes 
in patient’s daytime sleepiness and health-related quality of life respectively. After 
the trial significant changes were observed in mean ESS score (P=0.022), AHI 
(P˂0.001), MinO2 (P=0.008) and MeanO2 (P=0.003) following treatment with CPAP 
but no significant changes in the SAQLI score. After the treatment with OA, 
significant changes in mean ESS score (P=0.002) , AHI (P˂0.001), MinO2 (P=0.019) 
and the SAQLI score (P=0.044) were observed. However the MeanO2 was not 
significantly different. After the trial, no significant differences were seen in all the 
parameters measured between patients treated with OA and patients treated with 
CPAP. Patients in the OA group had shown more acceptance and more tolerance to 
the side effects associated with the use of OA as a means of treatment compared to 
patient in the CPAP group. In conclusion, even though CPAP remains the gold 
standard for the treatment of OSA but OA is an effective means of treatment to 
reduce AHI and day time sleepiness as well as improving MinO2 and health-related 
quality of life for patients who are suffering from mild to severe OSA. In this study, 
OA was found to be as effective as CPAP in treating OSA. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background  
The definition of obstructive sleep apnoea (OSA) is a cessation of air flow for 
10 seconds or more. On the other hand the definition of obstructive hypopnea is the 
reduction of 50% in air flow. The number of apnoea events per hour during sleep (AI 
= apnoea index) as well as the number of apnoea/hypopnea events per hour during 
sleep (AHI = apnoea hypopnea index) are recorded in an overnight sleep study. 
Obstructive sleep apnoea (OSA) is a widespread chronic condition affecting 3 
to 7% of the population (Bixler et al., 2001; Bixler et al., 1998; Young et al., 1993; 
Bearpark et al., 1995). Patients with OSA suffer from continuous complete or partial 
collapse of the upper airway during sleep, which causes sleep fragmentation and 
oxygen desaturation (Cistulli and Sullivan, 1993). Previous study reported that OSA 
is significantly prevalent in many of the developing as well as industrialised 
countries (Punjabi, 2008). Studies done by Young et al. (1997) and Davey (2003) 
suggested that the majority of patients (about 80-90 %) suffering from OSA remain 
undiagnosed due to the lack of awareness among the patients and the doctors. Many 
studies had shown that OSA if untreated can cause several cardiovascular 
complications such as hypertension as reported by Peppard et al. (2000), stroke, 
congestive heart failure and arterial fibrillation as reported by Shahar et al. (2001) 
and Ng et al. (2005).  
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There are three kinds of sleep apnoea: obstructive, central, and mixed central 
apnoea which is defined as a lack of airflow accompanied by a cessation of 
respiratory effort. Obstructive sleep apnoea OSA is by far the most common kind of 
apnoea documented. OSA occurs at sleep with periods of cessation of breathing, 
despite the presence of the inspiratory effort. This results in clinically obvious 
symptoms, such as sleep fragmentation, poor quality of sleep and sleepiness. This 
clinical manifestation was termed obstructive sleep apnoea syndrome (OSAS). It is 
not a new condition, but the true health risks have been identified only recently. 
Mixed apnoea has both central and obstructive component of sleep apnoea. 
Conservative treatment of OSA involves behaviour modification including 
weight loss, exercise, sleep posture and hygiene, alcohol avoidance and avoidance of 
certain medications. However specific treatment of OSA includes continuous 
positive airway pressure, oral appliances, and surgery. Nasal continuous positive 
airway pressure (CPAP) is the current gold standard treatment of choice. It is proven 
to be highly effective because it pneumatically splints the entire airway, regardless of 
regional pathophysiology (Montserrat et al., 2001). Unfortunately its hefty nature 
makes tolerance and compliance quite hard for many patients (Kribbs et al., 1993). 
This has led to research focusing on alternative treatment methods which are 
potentially as effective as CPAP, and well accepted. One example is oral appliance 
(OA) therapy, the most studied of which is the mandibular advancement splint 
(MAS). Some of the advantages of the OA as compared to CPAP are that it is 
portable, easier to be used, cheaper, do not need any power source and patients often 
prefer to use it. Recent practice parameters suggests that they are indicated for 
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patients with mild to moderate OSA, or for patients with severe OSA who are unable 
to accept CPAP or refuse treatment with CPAP (Kushida et al., 2006). 
 Most of the previous studies suggested that it is more advisable to use OA in 
long term treatment of OSA due to patient’s preference (Ferguson et al., 1996). It has 
also shown improvements in various polysomnographic indices, blood pressure, 
snoring, and sleepiness, neurocognitive functioning and quality of life. However, 
despite the growing evidence base for OA therapy, a number of limitations still exist 
and include: not being as effective overall as CPAP therapy, uncertainty about the 
effect of appliance design on treatment outcome and side effects, adherence to 
treatment, and potential long-term complications of treatment (Fritsch et al., 2001). 
Hence the overall aim of this study is to investigate the effectiveness of OA in 
the treatment of OSA and to compare it with the standard treatment of OSA the 
CPAP which will be of great clinical relevance and also will contribute to further 
understanding of the mechanisms of OA in the treatment of OSA. The OA used in 
this study was custom made to each patient and its’ design and function was inspired 
from the Twin Block functional appliance. Patients suffering from all grades of OSA 
severity (mild, moderate and severe) were included in the trial which was lacking in 
the previous studies comparing between the two means of treatment. 
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     1.2 Objectives 
1.2.1 General objectives 
To compare the effectiveness of oral appliance (OA) in comparison to 
continuous positive airway pressure (CPAP) in treatment of obstructive sleep apnoea 
(OSA). 
 
       1.2.2 Specific objectives 
1. To compare changes in excessive daytime sleepiness in OSA patients 
following treatment with OA and CPAP. 
2. To compare changes in apnoea hypopnea index (AHI) in OSA   
patients following treatment with OA and CPAP. 
3. To compare changes in minimum nocturnal arterial oxygen saturation 
in OSA patients following treatment with OA and CPAP. 
4. To compare changes in mean nocturnal arterial oxygen saturation in 
OSA patients following treatment with OA and CPAP. 
5. To compare changes in quality of life scores in OSA patients 
following treatment with OA and CPAP. 
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1.3 Research null hypothesis 
There is no difference between the effectiveness of OA and CPAP in terms of:  
1- Reducing the excessive daytime sleepiness in OSA patients. 
2- Reducing the AHI in OSA patients. 
3- Improving the minimum nocturnal arterial oxygen saturation in OSA 
patients.  
4- Improving the mean nocturnal arterial oxygen saturation in OSA patients. 
5- Improving the quality of life scores in OSA patients.                               
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CHAPTER 2 
Literature Review 
 
2.1 Epidemiology (Prevalence) 
 OSA is a common disease with a prevalence of 4% among males and 2% 
among females. The prevalence of sleep disordered breathing (SDB) (defined as AHI 
≥ 5 and without daytime sleepiness) is 9–28% among women and 17–26% for men 
(Young et al., 1993). OSA well known daytime symptoms are excessive daytime 
sleepiness (EDS), but other symptoms, such as low quality sleep, poor concentration, 
and fatigue are frequently reported (Littner et al., 2001). Despite its high prevalence, 
OSA often goes undiagnosed. For example, in the general population, according to 
an American investigation, the Wisconsin Sleep Cohort Study,  about 82% of males 
and 93% of females suffering from moderate to severe OSA had not been clinically 
diagnosed (Young et al., 1997).  
The occurrence of OSA is most common in the age group between 40 and 65 
years, and males have a higher prevalence of sleep apnoea than females in all age 
groups, with the highest prevalence between 40 and 49 years (Telakivi et al., 1987; 
Young et al., 1993). Females have the highest prevalence between 50 and 60 years of 
age. The severity of OSA increases with age in both males and females, but males 
have a consistently higher AHI for each age group. According to a recent 
epidemiologic study, there is a linear correlation between AHI and females age, in 
both obese and non-obese females. In males, the effect of age on AHI is different: 
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their BMI interacted in such a way that in obese men, the AHI increased from age 
20–40 years but remained stable after that (Gabbay and Lavie, 2012).  
The incidence of OSA has been much less studied than the prevalence. A 
longitudinal cohort study in the US communities assessed the incidence rate on two 
occasions, which were 5 years apart. Over the 5-year period, the overall incidence of 
moderate to severe OSA, defined by an AHI > 15, was 11% in males and 5 % in 
females (Newman et al., 2005).  
 
2.2 Pathogenesis 
 Sleep apnoea is a slowly progressive disorder (Young et al., 2002). The dilator 
muscles play a very important role to prevent the collapse of the pharyngeal airway 
which is the cause of almost all apnoea. The upper airway dilator muscles contract 
during each inspiration to stop the closure of the airway by suction and to insure the 
pharyngeal clearness. These muscles include the palatal muscles (levator veli, 
palatoglossus, and tensor veli palatine), supra-hyoid muscles (genioglossus, 
geniohyoid), infra hyoid muscles (sternohyoid, sternothyroid) and laryngeal muscles 
(cricothyroid and posterior cricoarytenoid) (Lee-Chiong et al., 2002). The activity of 
the upper airway dilator muscles is decreased during sleep, as well as a decrease in 
electromyogram (EMG) activity of genioglossus and tensor palatine, therefore 
predisposing to collapse of the pharyngeal airway (Tangel et al., 1991; Tangel et al., 
1992; Pack et al., 2006). 
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 When an individual sleeps the muscles tone in the whole body tends to 
decrease that includes the upper airway dilation muscles which tend to be in a state 
of relaxation. This will contribute in the narrowing of the upper way which will 
cause turbulent air flow and snoring vibration. In some individuals the upper airway 
dilator muscles relaxation may progress to cause a clinically significant airway 
narrowing or total collapse which will cause OSA (Douglas and Polo, 1994). Other 
changes in the upper airway can also occur either because of the snoring or the large 
swing in intraluminal pressure during sleep (Pack et al., 2006). Among these changes 
are denervation of soft palatal tissue and an inflammatory cell infiltration in both the 
mucosal and muscle layers in the upper airway (Friberg et al., 1998; Boyd et al., 
2004). These secondary changes have led to the belief that OSA can be caused by 
untreated chronic snoring (Friberg et al., 1998).  
 
2.3 Aetiological factors  
Previous studies had mentioned age, gender, snoring and obesity to be the main 
risk factors causing OSA (Young et al., 2002). Other secondary factors that might 
play a role in the development of OSA are medication and alcohol, menopause, 
hereditary factors, ethnicity, smoking and anatomical abnormalities (Strohl and 
Redline, 1996).  
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2.3.1 Gender 
Several previous studies have shown that males had significantly higher 
chances of developing OSA compared with females (Young et al., 1993). 
Anatomical differences between males and females are the possible reason. These 
differences are represented in the fact that males have more volume of fat in the 
pharyngeal walls, less genioglossal muscle activity, longer airway and higher 
pharyngeal resistance than females (Malhotra et al., 2002). A study by Ware et al. 
(2000) reported that the significant difference in prevalence of OSA between the 
male and female is most obvious in the age group between 40-60 years and there 
were almost no differences in the elderly. This might be caused by the fact that the 
female hormones helps to improve the stability of the upper airway (Popovic and 
White, 1998). Studies done by Ambrogetti et al. (1991) and Redline et al. (1994) 
suggested that the significant difference in prevalence might as well be caused by the 
reason that females usually do not report that they are suffering from snoring 
 
2.3.2 Age 
The majority of the previous studies done have shown that the risk of OSA 
increases with age (Grunstein et al., 1993; Young et al., 2002). Results from OSA 
studies done on individuals with the age of 65 or more had reported that older 
patients have about 13-62 higher risk of developing OSA compared to younger 
individuals (Sandberg and Delirium, 2000). But other studies have found that even 
though the prevalence of OSA increases with age younger individuals tend to be 
more aware of the importance of reporting snoring which is one of the main OSA 
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symptoms (Bixler et al., 1998; Lindberg et al., 1998). Studies investigating the 
relation between the type of OSA and age found that older individuals tend to have 
central apnoea in which the neuromuscular component plays a bigger role compared 
to younger individuals (Bixler et al., 1998).  
 
2.3.3 Obesity 
Almost all of the previous studies concluded that obesity is one of the main risk 
factors of OSA (Young et al., 1993; Sandberg and Delirium, 2000). An obese 
individual has more fat depositions in the pharyngeal walls which contribute to the 
narrowing of the upper airway which is a direct cause of OSA (Katz et al., 1990; 
Mortimore et al., 1998). The results from this study had shown that there was a 
significant difference in the neck circumference between individuals suffering from 
OSA and healthy individuals. The mean neck circumference was (43.7 cm) and         
(39.6 cm) respectively. 
Results from this study and other studies such as Davies and Stradling (1990) 
has shown the importance of neck circumference as predictor of association with 
OSA. However, another study had suggested BMI to be a better predictor of 
association between OSA and obesity than the neck circumference (Grunstein et al., 
1993).  
A study by Young et al. (2002) reported that according to several uncontrolled 
dietary and surgical weight loss trials there was a significant relationship between the 
individuals’ weight loss and the reduction of their AHI. Results from other controlled 
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trials reported about 47-60% reduction in AHI as a result of a weight loss of about 9-
17% (Smith et al., 1985; Schwartz et al., 1991). 
 
2.3.4 Snoring 
Snoring might increase the risk of developing OSA either directly or indirectly. 
Some studies reported that snoring might cause pharyngeal narrowing by reducing 
the activity of the pharyngeal dilator muscles (Deegan and McNicholas, 1995). 
Snoring can also cause pharyngeal narrowing  by vibration injury to the upper airway 
mucosa and/or the surrounding structures (Friberg, 1999). Snoring can also indirectly 
cause OSA as a marker of nasopharyngeal allergy. 
 
2.3.5 Soft tissue abnormalities 
Several studies had reported different soft tissue and anatomical abnormalities 
that might contribute in the development of the narrowing of the upper airway and 
eventually causing OSA (Hudgel, 1992; Deegan and McNicholas, 1995; Bassiri and 
Guilleminault, 2000). Among these abnormalities are the increase in the fat 
depositions in the lateral pharyngeal walls (Katz et al., 1990; Mortimore et al., 1998), 
enlarged tonsils and macroglossia (Schwab et al., 1995; Nelson and Hans, 1997), low 
hyoid bone position (Partinen et al., 1988; Sforza et al., 2000) and reduction in the 
length of the mandibular body and cranial base (Battagel and L'estrange, 1996; 
Battagel et al., 1998). Results from one trial conducted on 240 OSA patients reported 
that the most anatomical abnormality associated with OSA is narrowing of the 
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airway by the lateral pharyngeal walls followed by enlarged tonsils, enlarged uvula 
and macroglossia (Schellenberg et al., 2000).   
 
2.3.6 Ethnicity 
Several studies had been conducted before to investigate the relationship 
between ethnicity and OSA among them is a study done by Redline et al. (1997) 
which suggested that the prevalence of OSA is higher in African-American 
compared to Caucasians. Another study done by Kripke et al. (1997) conducted 
home questionnaire and sleep studies on 355 individuals living in San Diego reported 
a significantly higher risk factor for individuals from (Hispanic, Black and others) 
16.3%  compared to White individuals 4.9%.  
The relationship between ethnicity and the prevalence of  snoring and other 
OSA main symptoms was investigated by a study conducted  by Ng et al. (1998) in 
Singapore to compare between the three main races in Singaporean community. The 
results showed that Indians have the highest prevalence (10.9%) followed by Malays 
(8.1%) and Chinese (6.2%). The results from another study conducted in Malaysia on 
Malay security officers showed that there was a range of prevalence of the main 
symptoms of OSA with 45 out of 661 patients categorized in the high risk group for 
OSA (Hashim and Samsudin, 2014). 
Another study conducted in New Zealand compared the OSA in two races 
Polynesian and White (Coltman et al., 2000). The result showed that Polynesian 
males have higher OSA prevalence which might be due to the fact that they have 
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larger and more prognathic mandibles, wider neck circumference and larger 
craniofacial skeleton than White individuals.   
 
2.3.7 Hereditary factors 
Several previous studies had studied the possible relationship between the 
hereditary factor and the prevalence of the OSA (Mathur and Douglas, 1995; Redline 
et al., 1995). These two studies were conducted on first degree relatives and the 
results were independent from other risk factors like gender, age and obesity. Results 
from these studies have reported there were a significant relationship between the 
hereditary factor and the prevalence of OSA based on both OSA symptoms and sleep 
study. They also suggested that the overall relationship is not strong enough to justify 
screening of family members who are symptom free. 
 
2.3.8 Smoking 
Strong relationship between smoking and OSA was found by several studies 
among them are studies suggesting that smoking induce pharyngeal inflammation 
which causes narrowing of the upper airway (Wetter et al., 1994; Kashyap et al., 
2001). In a study, which focused on smoking, Wetter et al. (1994) also found that 
smoking significantly increase the risk of snoring (odds ratio = 2.3) as well as the 
occurrence of moderate to severe OSA (odds ratio = 4.4) OSA. A 10 years follow-up 
study conducted by Lindberg et al. (1998) reported that smoking might cause the 
development of snoring.  
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2.3.9 Menopause 
Studies have shown that the females have a low prevalence of OSA before 
menopause and one of the factors that might be involved is the preventive role of the 
female hormones that keep the tone of the pharyngeal dilator muscle and contribute 
to its activity (Popovic and White, 1998; Krystal et al., 1998). Studies that link the 
increase in OSA prevalence with the postmenopausal females are little but there is a 
widespread belief that menopause is among the risk factors of OSA. Results from 
two population based epidemiological studies support the claim reporting 0.6% OSA 
prevalence in premenopausal females compared to 2.7% in postmenopausal females 
(Bixler et al., 2001; Young et al., 2003).  
 
2.3.10 Medication and alcohol 
 Previously conducted studies have shown that sedative medications are among 
the risk factors that might cause respiratory depression and apnoea by decreasing the 
tone of the pharyngeal dilator muscles. Examples of these medications are 
antihistamines, benzodiazepines and morphine (Dolly and Block, 1982; Bresnitz et 
al., 1994). Even though there are studies  reported that alcohol can increase nasal and 
pharyngeal resistance in awake individuals (Robinson et al., 1985), other studies 
shown that alcohol consumption right before sleeping may cause respiratory 
disturbance during sleep (Tsutsumi et al., 2000; Scanlan et al., 2000). Another study 
conducted by Aldrich et al. (1999) investigated the long-time alcohol consumption 
effect on developing OSA by performing sleep study on 188 alcoholic individuals 
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undergoing alcoholism treatment. Results from this study reported a prevalence of 
17% in the 40-59 age group and 50% in the over 60 age group. 
 
2.4 Symptoms 
 The major symptoms of OSA are snoring, excessive daytime sleepiness (EDS) 
and deficits in neuropsychological function (Greenberg et al., 1987), which adversely 
impact on quality of life. Other symptoms that are associated with OSA are 
hypertension, myocardial infarction, stroke (Shahar et al., 2001; Weiss et al., 2007), 
heart failure (Leung and Bradley, 2001); Shahar et al. (2001), arrhythmias (Harbison 
et al., 2000), difficult anaesthesia (Loadsman and Hillman, 2001), insulin resistance 
(Brooks et al., 1994) and clotting problems (Chin et al., 1998). Symptoms in OSA 
are usually multiple and variable, occurring both at night (during sleep) and during 
the day. 
 
 2.4.1 Symptoms during sleep & day time  
The main symptoms that OSA patients suffers during sleep are heavy snoring, 
gasping for breath, nocturnal panic, chest discomfort, palpitations, disrupted sleep, 
night sweat, dry mouth, sore throat, gastro-oesophageal reflux and nocturnal diuresis. 
On the other hand symptoms that OSA patients suffer during daytime are excessive 
daytime sleepiness, morning headaches, erectile dysfunction, reduced concentration, 
memory disturbance, depression and impaired mood.  
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Overall, not all symptoms can be seen in one patient and symptoms are 
generally non-specific and can be confused and mixed with symptoms from other 
disorders like depression or hypothyroidism. Nevertheless, sleeping symptoms are 
more specific for OSA than daytime symptoms which tend to be caused by 
insufficient sleep even though not caused by OSA (Bassiri and Guilleminault, 2000). 
Daytime fatigue or sleepiness is the most common symptom in patients with OSA 
and may occur in both passive and active situations. Lack of snoring does not 
definitively exclude the diagnosis of OSA but practically all patients snore. Apnoea 
episodes are reported by almost three quarters of bed partners (Hoffstein et al., 
1995), around half of OSA patients report restlessness and excessive sweating and 
one quarter reports a choking sensation that interrupts sleep (Kales et al., 1985). 
 
2.5 Diagnosis 
Full medical examination is always the first step in the way to correctly 
diagnose an individual to be suffering from OSA. Perfect history taking should be 
undertaken using questionnaires about the patient’s habits such as sleeping habits, 
smoking, OSA symptoms that the patient might have and cardiovascular diseases. 
Height, weight, neck circumference and blood pressure should be measured and 
recorded. All these preliminary examinations are important but previous studies had 
suggested that the diagnosis of OSA cannot be confirmed from the patient history 
(Crocker et al., 1990; Viner et al., 1991), clinical examination (Viner et al., 1991) or 
observation during sleep (Haponik et al., 1984). 
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In order to confirm the diagnosis of OSA an overnight sleep study must be 
performed for each individual. In the past this study could only be conducted in the 
laboratory polysomnography. Recently, with the development of portable equipment 
that allows the patient to perform sleep study at home therefore, the sleep study has 
become easier than ever. 
Obstructive events cause either cessation or reduction of airflow despite the 
presence of respiratory efforts and an over compensatory response by the autonomic 
nervous system (Kushida et al., 2005; Dempsey et al., 2010). This condition results 
in significant arterial hypoxemia and arousals from sleep. The diagnoses of OSA 
should take into consideration both the clinical symptoms and the polysomnographic 
data obtained from the sleep study. During sleep symptoms of OSA which include 
heavy snoring and airflow interruptions are usually reported by the bed partner 
(Kushida et al., 2005). The severity of OSA which is determined by AHI correlates 
poorly with the severity of daytime symptoms as reported by Kushida et al. (2005). 
There is standardisation of the techniques of polysomnographic recording 
during sleep study which is used in the diagnosis of OSA (Iber et al., 2007). These 
techniques include recording of electroencephalography (EEG), electro-oculography 
(EOG), nasal and oral airflow, abdominal and chest movements, pulse oximetry, 
body position, electrocardiography (ECG), arousals and leg movements. AHI is an 
index that shows the number of the full and partial obstructive events that occur per 
hour during sleep. OSA severity is usually described as follows:  mild with AHI 
range from 5-15, moderate with AHI range from 15-30 and severe when the AHI is 
over 30. The oxygen desaturation index (ODI) on the other hand shows the number 
of at least 4% drops in blood oxygen levels per hour during sleep. The arousal index 
18 
 
(ARI) shows the number of arousals from sleep per hour and is an indicator of sleep 
fragmentation (Kushida et al., 2005). 
Total sleep time is an important variable because the diagnosis of OSA is based 
on an index value. Sleep recordings which is made by a portable recording system 
have to be based on the patient’s individual experience of sleep compared with a 
more accurate measurement of the sleep time using laboratory polysomnography. 
However, Franklin and Svanborg (2000) conducted a study on 100 patients to 
evaluate the accuracy of individual sleeping time with a polysomnographic 
registration. They found that the mean AHI based on the individual sleep time did 
not show any significant difference compared with the mean AHI based on EEG 
recorded total sleep time. 
 
2.6 Treatment 
The best treatment of OSA differs from one patient to another with many 
factors influencing the choice of the right treatment that is suitable for each 
individual. These factors include the sleep study findings, the severity of the 
symptoms and the patient’s motivation for treatment. The treatment method must be 
discussed with the patient and the sleep specialist to insure treatment success which 
will lead to improved sleep, daytime function and quality of life and will help to 
reduce medical complications of OSA. 
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2.6.1 Behavioural treatment 
Behavioural treatment basically means the reduction of all the risk factors that 
may cause the development of OSA for instance smoking which can cause upper 
airway inflammation, obesity which causes more fat deposition around the neck and 
alcohol consumption particularly near bedtime. Each patient should be advised to 
follow a weight loss programme, stop smoking and alcohol consumption. 
 
2.6.2 Positional therapy 
The way the patient sleep may contribute in the occurrence of OSA. For 
instance sleeping in the lateral position might reduce OSA by reducing pressure on 
the airway (Isono et al., 2002; Srijithesh et al., 2014). Sleeping in the lateral position 
might also prevent the tongue from falling back and block the airway causing OSA. 
It might be beneficial to try positional therapy with patients who are newly 
diagnosed with OSA before the decision of using other methods of treatment is 
taken. Some devices have been used to support OSA patients to remain sleeping in 
the lateral position. Other studies like Epstein et al. (2009) also recommended sleep 
positional therapy as an effective secondary treatment for patients with OSA. 
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2.6.3 Continuous Positive Airway Pressure (CPAP) 
CPAP applied to the upper airway through a mask attached to the patient’s face 
during sleep remains the gold standard treatment of choice. The advantages of 
treatment are still being shown but current evidence suggests improvements in 
sleepiness, neuropsychological performance and cardiovascular disease. 
Unfortunately acceptance and adherence remain a problem despite significant 
research in this area, and has led to the search for alternative treatments. 
 
2.6.3(a) Mechanisms of CPAP Action 
 The mechanism of CPAP action is thought to be by forming a diffuse 
‘pneumatic splint’ of the upper airway. Lung volume effects are also likely to be 
important since CPAP induced lung expansion has been shown to stimulate reflexes 
which increase upper airway tone (Series et al., 1990). It also cause a ‘tracheal tug’ 
which stiffens and stabilises the airway (Begle et al., 1990). 
 
2.6.3(b) Indications for CPAP Treatment 
 A study published in Chest recommended that CPAP should be the treatment 
method of choice to all OSA patients who are symptomatic and suffering from the 
following: EDS, impaired cognition, mood disorders, insomnia, cardiovascular 
disease, or stroke with an AHI > 5 events/hour (Loube et al., 1999). It was 
recommended that all patients with an AHI ≥ 30 events/hour be treated with CPAP 
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regardless of whether they are symptomatic or not because of the increased risk of 
hypertension (Young et al., 1997). The American Academy of Sleep Medicine 
guidelines, however, are slightly different recommending patients with an apnoea 
index (AI) > 20 events/hour or an AHI > 30 events/hour should receive CPAP 
regardless of symptoms (Chesson Jr et al., 1997). Patients with EDS and either an 
AHI > 10 events/hour, or a respiratory arousal index of > 10 events/hour also should 
receive CPAP.  
More recent practice parameters suggested by Kushida et al. (2006) concluded 
that CPAP is indicated for the treatment of all severities of OSA mild to severe 
because of its ability to improve EDS, lowering blood pressure in hypertensive 
patients and improving quality of life. Despite these practice parameters, treatment 
with CPAP has sometimes been regarded as controversial (Yim et al., 2007). Until 
recently, comparison studies have evaluated CPAP against conservative management 
or tablet placebo with varying results.  
With the invention of ‘sham’ CPAP some clinical trials showed interesting 
results. For example, a multi-centre, randomised, placebo-controlled trial of 
asymptomatic patients with AHI ≥ 30 events/hour showed no benefit with CPAP 
treatment after 6 weeks when compared with placebo i.e. sham CPAP (Barbé et al., 
2001). At the other hand, patients with an AHI from 5-15 events/hour who 
complained of EDS, had improved individual sleepiness, cognition, feelings of 
depression, and quality of life when treated with CPAP versus an oral control plate 
(Engleman et al., 1999). Patients, however, preferred the oral placebo and it is in this 
grade of OSA severity that treatment alternatives are likely to have their role. 
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2.6.3(c) Advantages of CPAP Treatment 
1-Daytime Sleepiness  
Sleep fragmentation caused by OSA affects sleepiness, memory, learning and 
performance. CPAP has been shown to improve daytime sleepiness both subjectively 
and objectively (Gay et al., 2006). Studies has also suggested that missing one night 
of CPAP reverses almost all of the previous improvements in alertness and 
sleepiness (Kribbs et al., 1993). 
 
2-Quality of Life  
 Quality of life studies have compared the impact of CPAP relative to placebo 
(Barnes et al., 2002; Engleman et al., 2002; Profant et al., 2003), conservative 
treatment (Redline et al., 1998; Ballester et al., 1999; Monasterio et al., 2001) or 
positional therapy (Jokic et al., 1999). These studies have used generic and disease 
specific measures, with some demonstrating significant improvements and others 
not. One trial conducted on a 40 OSA patients suffering from heart failure 
randomised patients to either 3 months of CPAP treatment or a control placebo 
group. The patients treated with CPAP showed improvements in cardiovascular 
functions, quality of life and sympathetic activities (Mansfield et al., 2004). 
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2.6.3 (d) Acceptance and Adherence to CPAP 
Although CPAP can be a very effective treatment in OSA, acceptance and 
adherence have been significant problems since the introduction of CPAP and remain 
a challenge to this day. Objective measurement studies of CPAP compliance show 
that only 46% of patients use CPAP for minimum of 4 hours/night for 70% of the 
week (Sanders et al., 1986), patients on average use CPAP for only 4.7 hours/night 
(Engleman et al., 1994) , and long-term studies show that 20% of patients stop CPAP 
all together (McArdle et al., 1999). Patients who are more likely to tolerate CPAP 
treatment including those with excessive daytime sleepiness (EDS) and severe 
hypoxaemia during sleep (Meurice et al., 1994), and those who underwent intensive 
educational/psychological intervention (Hoy et al., 1999; Hui et al., 2000). Patients 
who do not initiate the referral, those who live alone, those with a poor initial 
experience with CPAP, those with recent life events and those experiencing side 
effects (for example air leaks, nasal congestion) were found to adhere poorly to 
treatment (Sanders et al., 1986; Rolfe et al., 1991; Kribbs et al., 1993; Popescu et al., 
2001). 
A trial by Richards et al. (2007) randomised one hundred OSA patients into 
two 1 hour cognitive behavioural therapy (CBT) sessions or usual management. 
They found that CBT resulted in greater adherence of CPAP. Although the level of 
CPAP pressure does not seem to predict CPAP usage Douglas and Engleman (1998), 
many interventions have focused on delivering lower pressures. Auto-titrating 
(CPAP) machines deliver optimal pressures throughout the night recognizing that the 
amount of pressure needed can vary depending on sleep stage and body position. By 
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doing so, less pressure overall can be delivered, which may be more tolerable for the 
patient. 
 
2.6.3(e) Side Effects of CPAP 
As previously mentioned, adherence to CPAP relies upon the patient’s initial 
experience with the device. Side effects such as rhinorrhoea, nasal congestion and 
dryness, poor mask fitting, air leaks and mouth leaks are common. Minimizing these 
side effects as early as possible is likely to improve adherence (Yim et al., 2007). 
 
2.6.4 Surgery 
Surgery for OSA started before the development of CPAP and oral appliances. 
Patients often prefer such procedures because they want a permanent ‘cure’ rather 
than temporary relief. Unfortunately treatment outcomes are mixed and often do not 
deliver the desired outcome. Common surgical procedures such as palatal surgery, 
uvulopalatopharyngoplasty (UPPP), adenotonsillectomy and mandibular 
advancement generally are about modification of the upper airway, although more 
recently, obesity surgery has been increasingly performed. 
  
 
 
